
    
      This is a multicentre dose escalation and expansion, first-in-human study designed to
      evaluate the safety and tolerability of AZD9833, alone (Parts A and B) or in combination with
      palbociclib (Parts C and D) or in combination with everolimus (Parts E and F) or in
      combination with abemaciclib (Parts G and H), in women with endocrine-resistant ER+ HER2-
      breast cancer that is not amenable to treatment with curative intent.
    
  